DeMuth Peter 4

What Happened

• Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics (ELTX), received a derivative award of 52,832 shares on July 16, 2026. The filing reports the acquisition price as $0.00, indicating an award/grant rather than an open-market purchase or cash exercise. This is a grant of equity-linked instruments (options/awards) that vest over time rather than immediate share ownership.

Key Details

• Transaction date and price: 2026-07-16; 52,832 shares at $0.00 (transaction code A — Award/Grant).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Vesting: Per the filing footnote, 50% of the options vest on July 16, 2027 and the remaining 50% on July 16, 2028, subject to continued service.
• Filing timeliness: Form 4 filed 2026-07-17 (within the standard two-business-day reporting window).
• Note: This is a derivative award (option/award). The grant itself does not represent immediate tradable shares; future Form 4s would report exercises or sales.

Context

• Derivative awards (like options) typically require vesting and then exercise before resulting in owned shares; this grant vests over two years per the footnote. The Form 4 shows the award value as $0 (acquisition price), which is standard reporting for grants — it is not a cash purchase. Grants are a common component of executive compensation and do not by themselves indicate immediate buying or selling sentiment.